Biological Therapies for Atopic Dermatitis: A Systematic Review

Area of Science:

• Dermatology
• Immunology
• Pharmacology

Background:

• Atopic dermatitis (AD) is a prevalent, relapsing inflammatory skin condition.
• Biologic therapies are increasingly utilized for moderate-to-severe AD cases.

Purpose of the Study:

• To review and synthesize evidence on both approved and investigational biologic treatments for AD.
• To focus on biologics in Phase II and III clinical trials, evaluating their efficacy and safety.

Main Methods:

• Comprehensive literature search of PubMed, EMBASE, and ClinicalTrials.gov.
• Inclusion of randomized controlled trials (RCTs) and meta-analyses in English.
• Focus on biologics with high-level evidence for AD treatment.

Main Results:

• Eight classes of biologics were identified, including IL-4/IL-13 inhibitors and JAK inhibitors.
• Dupilumab demonstrated significant efficacy and safety in adult and pediatric AD patients.
• JAK inhibitors (baricitinib, abrocitinib, delgocitinib) showed strong therapeutic effects.

Conclusions:

• Dupilumab, baricitinib, abrocitinib, and delgocitinib are key biologics with robust efficacy and safety data for AD.
• Many other biologics are in early developmental stages, requiring further investigation.
• This review aids clinicians in selecting therapies and guides future research directions.